Archive · 13 Jun 2025
Wanbury Stock Soars: Ventura Sees 53% Upside Potential
A company called Wanbury, which makes medicine ingredients, has seen its stock price go up a lot in the last five years.
A financial firm called Ventura thinks the stock will continue to go up and recommends buying it.
They believe the company will make a lot more money in the coming years, selling both ingredients and branded medicines.
Wanbury has recovered from some past problems and is expanding its production.
Ventura thinks the stock could go up even further.
Wanbury Ltd. stock has surged over 1,475% in five years.
Ventura Securities initiated coverage with a 'buy' rating and a price target of ₹458.
Ventura projects revenue to reach ₹1,046 crore by FY28, with significant growth in EBITDA and net profit.
Wanbury has strong positions in Active Pharmaceutical Ingredients (APIs), particularly Metformin and Sertraline.
The company is expanding with a brownfield expansion at its Tanuku plant.
- Who
- Ventura Securities and Wanbury Ltd.
- What
- Ventura Securities initiated coverage on Wanbury Ltd with a 'buy' rating.
- When
- Over the next 24 months; Revenue projections from FY25 to FY28.
- Where
- Domestic market.
- Why
- Based on positive growth projections and strong earnings potential.
- Stock Recommendation
- Buy
- Price Target
- ₹458
- Current Market Price
- ₹299.35
- Potential Upside
- 53%
- 5-Year Stock Growth
- 1,475%
- Wanbury's Focus
- API and branded formulations
- API market share (Metformin)
- 10%
- API market share (Sertraline)
- 30%